FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1592-1594 October 23, 2003 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Strom, B. L. PubMed Citation

The prescription of medications has long been the most frequent therapeutic intervention in medicine. In 2000 in the United States, 173 million people filled 2.2 billion outpatient prescriptions, accounting for $103 billion in expenditures. Because all medications have risks, the appropriate therapeutic use of pharmaceutical agents requires quantitative information on safety as well as efficacy.

In this issue of the Journal, a thoughtful investigation reported by Strom and colleagues (pages 1628–1635) shows that patients who have had a hypersensitivity reaction to sulfonamide antibiotics are no more likely to have a reaction to nonantibiotic sulfonamides than are patients who have had . . . [Full Text of this Article]

Source Information

From the Division of Pharmacoepidemiology, Department of Preventive Medicine, and the Geriatric Research, Education and Clinical Center, Nashville Veterans Affairs Medical Center, Nashville.

This article has been cited by other articles:

• Winkelmayer, W. C., Setoguchi, S., Levin, R., Solomon, D. H. (2008). Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy. Arch Intern Med 168: 2368-2375 [Abstract] [Full Text]  
• Wang, T. MSc, Collet, J.-P. PhD MD, Shapiro, S. PhD, Ware, M. A. MBBS MSc (2008). Adverse effects of medical cannabinoids: a systematic review. CMAJ 178: 1669-1678 [Abstract] [Full Text]  
• Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W. (2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 167: 1041-1049 [Abstract] [Full Text]  
• Riehl, C. (2006). Feeling Better: A Comparison of Medical Research and Education Research. EDUCATIONAL RESEARCHER 35: 24-29 [Abstract]  
• Gurwitz, J. H. (2006). Serious Adverse Drug Effects -- Seeing the Trees through the Forest. NEJM 354: 1413-1415 [Full Text]  
• Navarro, V. J., Senior, J. R. (2006). Drug-Related Hepatotoxicity. NEJM 354: 731-739 [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]  
• Chou, R., Helfand, M. (2005). Challenges in Systematic Reviews That Assess Treatment Harms. ANN INTERN MED 142: 1090-1099 [Abstract] [Full Text]  
• Psaty, B. M., Furberg, C. D., Ray, W. A., Weiss, N. S. (2004). Authors' Reply to Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis". JAMA 292: 2658-2659 [Full Text]  
• Stricker, B. H., Psaty, B. M (2004). Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47 [Full Text]